Human Genome 2nd lupus trial succeeds, shares soar

shares were trading at just 45 cents each. But those who maintained the faith, including shareholders such as Fidelity Investments, Barclays Global Investors, T. Rowe Price and Taube Hodson Stonex Partners, have done spectacularly well. Top shareholder...